The analysis showed that TNXB was upregulated in patients with bladder cancer (BLCA), cervical cancer (CESC), colon cancer (COAD), and breast cancer (BRCA) (Fig. S6A), while SPON1 was upregulated in patients with LNM in thyroid cancer (THCA) and bladder cancer (Fig. S6B). Here, TNXB is linked to bladder transitional cell carcinoma.